| Recruiting | Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients NCT07481851 | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital | — |
| Recruiting | CD70-targeted immunoPET Imaging of Kidney Cancer NCT06680089 | RenJi Hospital | Phase 2 |
| Recruiting | Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma NCT06676527 | Jinling Hospital, China | — |
| Recruiting | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer NCT06353906 | The Netherlands Cancer Institute | Phase 2 |
| Recruiting | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab NCT06237920 | The Netherlands Cancer Institute | Phase 2 |
| Recruiting | A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest NCT05899361 | Dana-Farber Cancer Institute | N/A |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy NCT05887245 | Centre of Postgraduate Medical Education | — |
| Unknown | To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Su NCT05308771 | Centre Hospitalier Universitaire de Tivoli | N/A |
| Unknown | Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma NCT05135832 | Herlev and Gentofte Hospital | N/A |
| Unknown | Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen NCT05135520 | Seoul National University Bundang Hospital | N/A |
| Unknown | Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000). NCT05025930 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Unknown | Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) NCT04922047 | RenJi Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations NCT04579380 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Withdrawn | Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery NCT04630483 | Medipol University | — |
| Recruiting | Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy NCT04442724 | Cedars-Sinai Medical Center | N/A |
| Unknown | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma NCT04644432 | Herlev and Gentofte Hospital | Phase 2 |
| Completed | Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Popula NCT04052113 | AstraZeneca | — |
| Completed | LPN in Patients With High-complex Renal Tumors NCT04933604 | Samsun Liv Hospital | — |
| Completed | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NCT03636256 | NanOlogy, LLC | Phase 1 / Phase 2 |
| Completed | Laparoscopic Partial Nephrectomy for cT1 Tumors NCT04213157 | Samsun Liv Hospital | — |
| Unknown | Genetic Testing in Upper Tract Urothelial Carcinoma (UTUC): the Epicheck Study NCT04702347 | Fundacio Puigvert | — |
| Completed | Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer NCT03081858 | Lipac Oncology LLC | Phase 1 / Phase 2 |
| Completed | Pre-Operative Single Shot Rectus Sheath Block NCT03458598 | University of Alberta | N/A |
| Unknown | Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy NCT03595813 | Institut Paoli-Calmettes | N/A |
| Terminated | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer NCT03288545 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer NCT03219333 | Astellas Pharma Inc | Phase 2 |
| Active Not Recruiting | Savolitinib vs. Sunitinib in MET-driven PRCC. NCT03091192 | AstraZeneca | Phase 3 |
| Completed | A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery NCT03010813 | Chinese University of Hong Kong | N/A |
| Completed | Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of NCT02780687 | Boehringer Ingelheim | Phase 2 |
| Terminated | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer NCT02543645 | Celldex Therapeutics | Phase 1 |
| Terminated | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma NCT02386111 | Celldex Therapeutics | Phase 1 |
| Completed | Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen NCT05113134 | Seoul National University Bundang Hospital | N/A |
| Completed | Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy NCT04649970 | Université de Sousse | — |
| Completed | Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NCT02891460 | UroGen Pharma Ltd. | N/A |
| Completed | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer NCT01454089 | Achieve Life Sciences | Phase 2 |
| Terminated | Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer NCT01155791 | Sandy Srinivas | Phase 1 |
| Completed | Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-R NCT00374868 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen NCT00191971 | Eli Lilly and Company | Phase 2 |
| Terminated | Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer NCT00226954 | Stanford University | Phase 2 |
| Completed | Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium NCT00034177 | Achieve Life Sciences | Phase 2 |
| Terminated | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for NCT00384891 | Medical Enterprises Europe B.V. | Phase 3 |
| Completed | Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer NCT00151034 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples NCT00001814 | National Cancer Institute (NCI) | — |
| Withdrawn | SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolut NCT02254915 | Medical Enterprises Europe B.V. | Phase 3 |
| Completed | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer NCT00134186 | Pharmacyclics LLC. | Phase 2 |
| Completed | A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma NCT00035061 | Eli Lilly and Company | Phase 2 |
| Completed | A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Ca NCT00034593 | Eli Lilly and Company | Phase 2 |